Research Keyword: Candida infections

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

Read More »

Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistant Candida species

mycolabadmin

Researchers tested whether three cancer drugs (panobinostat, tamoxifen, and miltefosine) could enhance the effectiveness of common antifungal medications against drug-resistant yeast infections. When combined with antifungals, some of these cancer drugs showed promise in killing resistant Candida species, though the effectiveness varied depending on which type of yeast was being treated. These findings suggest that combination therapies using already-approved drugs could help treat difficult fungal infections in cancer patients.

Read More »

Synthesis, Physicochemical Properties and Anti-Fungal Activities of New Meso-Arylporphyrins

mycolabadmin

Researchers created three new porphyrin compounds that effectively kill fungal infections like Candida and athlete’s foot fungi. These compounds can also generate singlet oxygen when exposed to light, making them potentially useful for photodynamic therapy treatments. Testing showed they inhibited fungal growth at relatively low concentrations, suggesting they could become new antifungal medications.

Read More »

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading infectious disease expert, discusses his 48-year career studying fungal infections, particularly cryptococcal meningitis. He reflects on the dramatic transformation of HIV/AIDS from a fatal disease to a manageable chronic condition and emphasizes that antifungal resistance is less concerning than the underlying diseases that complicate treatment. Perfect advocates for developing more potent antifungal drugs that work faster, and discusses promising approaches like molecular diagnostics and immune-based therapies to improve patient outcomes.

Read More »

Is metabolic generalism the Breakfast of Champions for pathogenic Candida species?

mycolabadmin

This review examines how different Candida species, including the common cause of yeast infections (C. albicans) and the more dangerous bloodstream pathogen (C. glabrata), survive in the human body. While most pathogenic Candida species are metabolic generalists that can eat many different nutrients, the review shows that C. glabrata is a specialist that has found alternative strategies to thrive. Understanding these metabolic strategies is important for developing better treatments and fighting antifungal resistance.

Read More »
Scroll to Top